Clinical Applicability of Early Hemidiaphragmatic Paralysis Monitoring After Supraclavicular Brachial Plexus Block [Letter]
Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-2
DOI: 10.2147/dddt.s640957 ↗Kurz gefasst
Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Yiwen Hong. Beteiligte Einrichtung: West China School of Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
We read with interest the randomized controlled trial by Bao et al examining the early temporal progression of hemidiaphragmatic paralysis (HDP) after ultrasound-guided supraclavicular brachial plexus block (SCBPB) with 20 mL versus 30 mL of 0375% ropivacaine. 1 The authors are to be commended for using serial diaphragmatic compound muscle action potential (Dia CMAP) measurements to show that phrenic nerve involvement may be detected within 5 minutes and is substantially more frequent with the larger volume.However, two aspects of the clinical interpretation deserve further discussion.First, the study population may not represent the patients in whom HDP is most likely to alter perioperative management.The trial enrolled adults with American Society of Anesthesiologists physical status I-II and a body mass index of 18-28 kg/m 2 , while excluding those with moderate-to-severe impairment of pulmonary function.This selection is understandable for characterizing the electrophysiological time course of HDP, but it limits the direct translation of the findings into respiratory safety decisions.In this relatively healthy cohort, HDP occurred in 34.3% of patients receiving 20 mL and 65.7% of those receiving 30 mL, whereas only ten patients reported transient dyspnea and only one developed oxygen desaturation.Thus, the study convincingly demonstrates subclinical phrenic nerve involvement, but it cannot determine whether the 20-mL regimen is sufficiently safe for patients with limited pulmonary reserve.This distinction is clinically important because reducing the volume to 20 mL lowered, but did not eliminate, HDP.Therefore, 20 mL should be interpreted as a risk-reducing rather than a genuinely diaphragm-sparing regimen.In vulnerable patients, the relevant clinical decision may not simply be whether to use 20 or 30 mL, but whether SCBPB is the most appropriate approach.Hong et al reported that costoclavicular block reduced the incidence of HDP from 475% to 11.4% compared with supraclavicular block and better preserved pulmonary function.2 Petrar et al similarly found a lower incidence of HDP with an infraclavicular than with a supraclavicular approach 3 Future trials should therefore compare 20-mL SCBPB with below-clavicle alternatives in patients with respiratory comorbidities.Such studies should evaluate block effectiveness and respiratory safety concurrently, including supplemental block requirements, conversion to general anesthesia, opioid rescue, forced vital capacity, dyspnea, oxygen requirement, and unplanned postoperative observation.This design would better address the clinical trade-off between reliable surgical anesthesia and preservation of respiratory function.Second, the recommendation that respiratory monitoring should begin within 5 minutes and continue for at least 20 minutes may require further qualification.In routine practice, standard cardiorespiratory monitoring is already established before block placement.The more actionable questions are which patients require diaphragm-specific assessment and when enhanced respiratory observation can be safely discontinued.The reported plateau in HDP incidence between 20 and 30 minutes was based on the proportion of patients crossing the threshold of a ≥50% reduction in Dia CMAP amplitude.However, the mean Dia CMAP amplitude continued to decline significantly during the same Drug Design, Development and Therapy 2026:20 640957 1
Autor:innen und Institutionen
- West China School of Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Zitieren
APA
Hong, Y. (2026). Clinical Applicability of Early Hemidiaphragmatic Paralysis Monitoring After Supraclavicular Brachial Plexus Block [Letter]. Drug Design, Development and Therapy, Volume 20, 1-2. https://doi.org/10.2147/dddt.s640957
Vancouver
Hong Y. Clinical Applicability of Early Hemidiaphragmatic Paralysis Monitoring After Supraclavicular Brachial Plexus Block [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-2. doi:10.2147/dddt.s640957
BibTeX
@article{Hong2026,
author = {Hong, Yiwen},
title = {Clinical Applicability of Early Hemidiaphragmatic Paralysis Monitoring After Supraclavicular Brachial Plexus Block [Letter]},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--2},
doi = {10.2147/dddt.s640957}
}
EUVIMED